Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
~083SS
Our Ref.: IH-76-X
POWDERY PHARMACEUTICAL COMPOSITION
The present invention relates to a powdery
pharmaceutical composition con~aining a benzoyl urea
compound as the main component.
Heretofore, a benzoyl urea compound represented by
the following formula I is per se known:
~ CONHCONH ~ ~Z2 (I)
wherein X is a halogen atom or a nitro group, Y is a
hydrogen atom, a halogen atom, a nitro group or a
trifluoromethyl group, Zl is a halogen atom or a
trifluoromethyl group, Z2 is a hydrogen atom or a halogen
atom, and A is =CH- or a nitrogen atom.
Further, it is known that such a benzoyl urea
compound shows an excellent antitumorous action (e.g.
Japanese Unexamined Patent Publications No. 109721/1982,
No. 1670/1986, No. 93163/1986 and No. 205257/1986).
This compound is hardly soluble in water and thus poor in
the absorbability e.g. from the gut. Accordingly, in
2~083SS
-- 2 --
order to obtain an adequate antitumorous action, it is
necessary to increase the dose, and there is a
possibility of adverse effects by such a large dose.
Under the circumstances, some pharmaceutical
compositions have been proposed which are capable of
providing excellent absorbability from the gut for the
benzoyl urea compound of the formula I (Japanese
Unexamined Patent Publication No. 185013/1987 and
European Unexamined Patent Publication No. 264904).
From the viewpoint of drug formulation engineering,
in the case of such pharmaceutical compositions excellent
in the absorbability, they are preferably in a powder
form so long as they have such characteristics as being
free from blocking and excellent in the flowability,
since the compositions in a powder form are convenient
for handling during formulation, packaging or
subdividing, they can easily be administered to patients,
and the absorbability of the benzoyl urea compound of the
formula I e.g. from the gut will thereby be improved.
Accordingly, it is an object of the present invention
to provide a pharmaceutical composition containing a
benzoyl urea compound of the formula I, which has
excellent flowability and little blocking tendency, when
formed into a powdery drug formulation.
The present inventors have conducted various studies
in view of the above problems and have found it possible
to obtain a powdery pharmaceutical composition having
Z0083S5
-- 3 --
improved flowability and little blocking tendency by
incorporating a specific disintegrator, a specific
dispersant and a specific fluidizer, preferably in a
specific order, to the benzoyl urea compound of the
formula I. The present invention has been accomplished
on the basis of this discovery.
Namely, the present invention provides a powdery
pharmaceutical composition comprising a benzoyl urea
compound of the formula:
~CONIICONU~ N~ (I)
wherein X is a halogen atom or a nitro group, Y is a
hydrogen atom, a halogen atom, a nitro group or a
trifluoromethyl group, Zl is a halogen atom or a
trifluoromethyl group, Z2 is a hydrogen atom or a halogen
atom, and A is CH or a nitrogen atom, as an active
ingredient, a nonionic surfactant as a dispersant, at
least one member selected from the group consisting of
sugar, sugar-alcohol and a nonionic surfactant as a
disintegrant, and anhydrous silicic acid as a fluidizer.
Particularly, the present invention provides a
powdery pharmaceutical composition in the form of freeze-
dried formulation manufactured by a process which
2~ comprises pulverizing the benzoyl urea compound in an
aqueous solution containing the dispersant, adding the
disintegrant to the resulting liquid formulation,
znos3ss
lyophilizing the mixture, and adding the fluidizer
thereto.
Now, the present invention will be described in
detail with reference to the preferred embodiment.
The benzoyl urea compound of the formula I as the
present invention includes, for example, compounds of the
following formulas:
~CONHCONH~ 4~;3 CF3
Cl Cl (Compound No. 1)
. .
~COWHCONH ~ O ~ ~ I
(Compound No. 2)
~ OwHCONB ~ N ~
(Compound No. 3)
CONHCONH- ~ ~ Br
N02 Cl
(Compound No. 4)
~ CONHCONH 4~ YN~
(Compound No. 5)
Zn(~8355
-- 5 --
CONIICONH ~ ~/ ~ Cl
o N02
2 (Compound No. 6)
CONHCONH ~ ~ Cl
O~ Cl (Compound No. 7)
The benzoyl urea compound of the formula I is per se
known and can be produced by the method described in
Japanese Unexamined Patent Publication NO. 109721/1982 or
by a method similar thereto.
For the preparation of the pharmaceutical composition
of the present invention, the benzoyl urea compound of
the formula I is preferably as fine as possible.
The dispersant used in the present invention serves
as a dispersing agent when the benzoyl urea compound of
the formula I is suspended and pulverized in water. A
nonionic surfactant may be used as the dispersant in the
present invention without any particular limitation so
long as the object of the present invention can thereby
be attained, and it can be used as a pharmaceutically
acceptable additive. Particularly preferred is the one
in which the hydrophile-lipophile balance is more than 3.
Specific examples of such a dispersant include a
polyoxyethylene hardened castor oil, a polyoxyethylene
polyoxypropylene glycol, a sugar fatty acid ester, a
2C~083SS
glycerine fatty acid ester, a sorbitan fatty acid ester,
a propylene glycol fatty acid ester, a polyglycerine
fatty acid ester, a polyoxyethylene sorbitan fatty acid
ester, a polyoxyethylene sorbit fatty acid ester, a
polyoxyethylene glycerine fatty acid ester, a
polyethylene glycol fatty acid ester and a
polyoxyethylene castor oil. Among these nonionic
surfactants, preferred are the polyoxyethylene hardened
castor oil, the polyoxyethylene polyoxypropylene glycol
and the polyglycerine fatty acid ester.
The disintegrant in the present invention is
incorporated primarily to enhance the granularity and
disintegratability at the time of lyophilizing the
benzoyl urea compound of the formula I.
As such a disintegrant, there may be mentioned a
sugar, a sugar alcohol and a nonionic surfactant.
As the sugar for the disintegrant, there may be
mentioned a monosaccharide (such as glucose or fructose),
a disaccharide (such as lactose or sucrose) and a
polysaccharide (such as starch, dextrin or cellulose).
As the sugar alcohol for the disintegrant, there may
be mentioned mannitol and sorbitol.
The nonionic surfactant useful as the disintegrant
includes, for example, a polyoxyethylene hardened castor
oil, a polyoxyethylene polyoxypropylene glycol, a sucrose
fatty acid ester, a glycerine fatty acid ester, a
sorbitan fatty acid ester, a propylene glycol fatty acid
Z(~083SS
ester, a polyglycerine fatty acid ester, a
polyoxyethylene sorbitan fatty acid ester, a
polyoxyethylene sorbit fatty acid ester, a
polyoxyethylene glycerine fatty acid ester, a
polyethylene glycol fatty acid ester and a
polyoxyethylene castor oil.
The nonionic surfactant is preferably used as the
disintegrant. Particularly preferred is the sucrose
fatty acid ester or polyoxyethylene polyoxypropylene
glycol.
Although the same nonionic surfactant may be used
both as the dispersant and as the disintegrant, different
ones are preferably used. For example, when the`
polyglycerine fatty acid ester (e.g. decaglycerine
monolaurate) or the polyoxyethylene hardened castor oil~
(e.g. polyoxyethylene hardened castor oil 60) is used as
the dispersant, it is preferred to use the sucrose fatty
acid ester as the disintegrant.
The fluidizer used in the present invention has
functions to improve the flowability and to prevent the
powder from blocking when the pharmaceutical composition
is formulated in a powder form. As the fluidizer in the
present invention, anhydrous silicic acid is employed.
As the anhydrous silicic acid, light anhydrous silicic
acid may be mentioned.
The pharmaceutical composition of the present
invention, particularly the freeze-dried formulation, can
Z008355
-- 8 --
be prepared by pulverizing the benzoyl urea compound of
the formula I in an aqueous suspension containing the
dispersant, then adding the disintegrant thereto,
lyophilizing the mixture, and adding the fluidizer
thereto.
The pulverization is carried out preferably in a wet
system. The pulverization in a wet system is a method
wherein the material to be pulverized is rotated or
shaked together with beads (particularly glass beads) in
the liquid containing a dispersant. A machine such as
Dino-mill (KDL type, made by Willy A ~achofen Company)
may be used for the method; At the time of the
pulverization, the concentration of the benzoyl urea
compound in the aqueous solution is from 1 to 70%,
preferably form 20 to 50%, by weight/volume. The
concentration in such a range is preferable particularly
when Dino-mill is used for pulverization in a wet system.
The concentration of a nonionic surfactant as the
dispersant is from 1 to 30%, preferably from 2 to 20%, by
weight/volume. The diameter of the glass beads to be
used, is usually in a range of from 0.1 to 1.5 mm,
- preferably from 0.25 to 0.5 mm. The pulverization time
is usually in a range of from 5 to 60 minutes.
The composition which has been pulverized in a wet
system by using the above mentioned conditions, has a
mean particle diameter of from 0.2 to 1.0 ~um (as measured
by a photo scattering method).
2~Q83S5
g
After the pulverization in a wet system, the glass
beads are removed by a sieve. The disintegrant is then
added to the liquid of the pulverized benzoyl urea
compound of the formula I, followed by lyophilization.
The concentration of the disintegrant is in a range of
from 1 to 90~, preferably from 10 to 70~, by
weight/volume.
After the lyophilization, the fluidizer is uniformly
mixed to the freeze-dried powder to obtain a
pharmaceutical composition of the present invention in a
particularly preferred form of a freeze-dried
formulation. The amount of the fluidizer to be
incorporated here is usually from 1 to 20 parts by
weight, preferably from 4 to 20 parts by weight, relative
to 100 parts by weight of the dried powder.
- The pharmaceutical composition, particularly the
freeze-dried formulation, of the present invention,
preferably has a composition by a weight ratio of e.g.
benzoyl urea compound of the formula
I:dispersant:disintegrant:fluidizer = 1 to 70:1 to 30:1
to 90:1 to 20, preferably 20 to 50:2 to 10:10 to 70:4 to
20.
The pharmaceutical composition, particularly the
freeze-dried formulation, of the present inventlon can
further be formed into various optional drug formulations
by conventional methods. Such optional drug formulations
include, for example, formulations for oral
20083SS
-- 10 --
administration sùch as pulveres, microgranules, granules,
capsules and tablets.
For the preparation of such formulations, starch,
cellulose, lactose, sodium carboxymethyl starch, sodium
carboxymethyl cellulose, etc. may be used as excipients.
The pharmaceutical composition, particularly the
freeze-dried formulation, of the present invention is
usually orally administered to mammals including human,
cattle, horses, dogs, rats and mice. The dose may vary
depending upon e.g. the diseased state, the sex, the body
weight and the type of formulation. However, in the case
of oral administration of the composition of the present
invention against human malignant lymphoma or lung
cancer, a daily dose of the benzoyl urea compound of the
formula I for an adult is from 5 to 100 mg/kg body
weight, and such a dose is administered from onae to
third times per week.
The powdery pharmaceutical composition, particularly
the freeze-dried formulation, of the present invention
has flowability and anti-blocking tendency and is
excellent in the granularity, the disintegratability and
the stability. Further, the absorbability of the benzoyl
urea compound of the formula I from the gut is thereby
remarkably improved.
Accordingly, by using the pharmaceutical composition,
particularly the freeze-dried formulation, of the present
invention, the handling for the preparation of drug
zno83s5
-- 11 --
ormulations or for packaging or subdividing, will be
easy, and the administration to a patient will be easy.
Further, it i5 thereby possible to reduce the dose of the
benzoyl urea compound o the formula I, whereby it is
possible to reduce the pain to the patient during the
administration or to reduce side effects.
Now, the present invention will be described in
further detail with reference to Examples and Test
Examples. However, it should be understood that the
present invention is by no means restricted to such
specific Examples.
EXAMPLE 1
Compound 3 (20 9) was suspended in 50 me of a 5 w/v%
polyoxyethylene hardened caster oil (HCO-60) aqueous
solution and subjected to wet pulverization by Dino-mill
(3,000 rpm for 45 minutes) using 50 9 glass beads
(diameter: 0.25-0.5 mm). After completion of the
pulverization, glass beads were removed by a sieve to
obtain a wet-pulverized formulation of Compound 3. To 50
me of this liquid formulation, 20 9 of sucrose mono-
palmitic acid ester (P1670, manufactured by ~itsubishi
Kasei Corporation) was added, and the mixture was freezed
by dry ice-methanol and subjected to vacuum drying for 24
hours to remove water. Further, 4 9 of light silicic
acid anhydride was added and mixed thereto to obtain a
pulvis.
'~908355
- 12 -
EXAMPLE 2
Compound 3 (15 g) was suspended in 50 me of a 5 w/v%
polyoxyethylene polyoxypropylene glycol (Pluronic F68)
aqueous solution and subjected to wet pulverization by
Dino-mill (3,000 rpm for 45 minutes) using 50 g of glass
beads (diameter: 0.25--0.5 mm). Aftex completion of the
pulverization, the glass beads were removed by a sieve to
obtain a wet pulverized formulation of Compound 3.
To 50 me of this liquid formulation, 30 g of sucrose
monopalmitic acid ester (Pl670, manufactured by
Mitsubishi Kasei Corporation) was added, and the mixture
was freezed by dry ice-methanol and then subjected to
vacuum drying for 24 hours to remove water. Further, 4 g
of light silicic acid anhydride was added and mixed
- 15 thereto to obtain a pulvis.
EXAMPLE 3
A pulvis was prepared in the same manner as in
Example 2 except that instead of the polyoxyethylene
polyoxypropylene glycol, decaglycerin monolaurate
(Decaglin l L, manufactured by Nikko Chemical Company)
was used.
EXAMPLE 4
In the same manner as in Example 3, a pulvis having
the following composition was prepared.
Z()08355
- 13 -
Compound 3 (main ingredient) 316 mg
Decaglycerin monolaurate ~decaglycerin 1 L,
dispersant) 53 mg
Sucrose monopalmitic acid ester (P-1670,
disintearater) 631 mq
Total 1000 mg
To 100 mg of the above pulvis, 8 mg of light silicic
acid anhydride and 100 mg of corn starch were added, and
after an addition of isopropyl alcohol, the mixture was
kneaded, then dried and sieved through a screen of 30
mesh to obtain granules ~wet system granulation).
Further, using crystalline cellulose or lactose
instead of the corn starch, granules were prepared in the
same manner.
ExAMpLE 5
To 100 mg of the pulvis in Example 4, 10 mg of sodium
carboxymethylcellulose, 4 mg of light silicic acid
anhydride and 2 mg of magnesium stearate were added. The
mixture was mixed and tabletted. The tabletts were
pulverized in a mortar and then sieved through a screen
to obtain granules of from 12 to 50 mesh (dry system
granulation).
Further, using 50 mg of corn starch or 30 mg of
sodium carboxymethylstarch, instead of 10 mg of sodium
carboxymethylcellulose, granules were prepared in the
same manner.
211(~83S5
- 14 -
TEST EXAMPLE 1
Known composition:
Compound 3(main ingredient) 316 mg
Decaglyne l-L (dispersant) 53 mg
Sucrose fattY acid ester P-1670 (disinte~rater)631 mq
Total 1000 mg
On the basis of the above known composition,
improvement of the flowabiliaty of the powdery
composition and prevention of blocking were studied to
improve the easiness for administration or the efficiency
for the production, particularly for subdivided
packaging.
After adding and mixing magnesium stearate, light
silicic acid anhydride or a mixture thereof, as the
fluidizer, to the above known composition, at a
concentration as shown bellow, the flowability and
blocking tendency were visually observed.
Amount of magnesium stearate: 1, 2, 4, 6 or 8%
Amount of light silicic acid anhydride: 1, 2, 4 or 8%
Amount of 4% magnesium stearate + 2% light silicic
anhydride: 6~
After adding and mixing magnesium stearate, light
silicic acid anhydride or a mixture thereof, as the
fluidizer, to the above known composition, the
flowability and blocking tendency of the composition,
were as follows.
Namely, by an addition of magnesium stearate in an
znos3ss
- lS -
amount of`;at least 4%r an improvement in the flowability
was observed, but even by an addition of 8%l the
composition underwent coagulation simply by lightly
pressing it with a finger and showed a blocking
phenomenon. By an addition of light silicic anhydride in
an amount of at least 2%, an improvement in the
flowability was observed, and by the addition in an
amount of 8%, adequate improvement in the anti-blocking
tendency was observed. By an addition of 4% magnesium
stearate + 2% light silicic anhydride, a blocking
phenomenon was observed.
TEST EXAMPLE 2
Pulvis according to the present invention:
Compound 3 292 mg
Decaglin l-L 49 mg
P-1670 585 mg
Liaht silicic acid anhYdride 74 mq
Total 1000 mg
The physical properties of the above dust of the present
invention will be shown below. The physical properties
were measured by a powder tester (manufactured by
Hosokari Micron).
1. Flow properties
Angle of repose: 40
Spatula angle: 58
Loose apparent specific gravity: 0.43 g/me
Packed apparent specific gravity: 0.57 g/me
~83~
- 16 -
Compressibility: 24.5%
Uniformity: 2.94
Degree of flowability: Fairly good
2. Jetting properties
Flow index: 72.5
Disintegration angle: 22
Difference angle: 18
Dispersibility: 7.2%
Degree of jetting: Fairly strong
TEST EXAMPLE 3 (Absorption by rats)
With respect to the pulvis according to the
composition of the present invention and the pulvis
according to the known composition, the concentrations of
Compound 3 in the plasma of the respective rats by oral
administration and AUC were compared. The results are
shown in Table 1.
The conditions were as follows:
Dose: 50 mg (as Compound 3)/5 me of water/~g of the
body weight, was orally administered.
Animals: SD type male rats (body weight: 180-200 9),
five animals per group
Blood sampling: 1, 3, 6, 8, 10 and 24 hours later
Quantitative analysis:
HPLC method [Column: C18 reversed phase system;
Mobile phase: acetonitrile-
water system;
Detection: ultraviolet absorption
(wavelength: 265 nm)]
znos3ss
- 17 -
~able 1
_ Pulvis of Known
the present pulvis
invention
Immediately
Concentration administra- 0 0
(~g/me) tion
1 hr 0.28iO.03 0.24iO.03
2 hrs 0.46+0.09 0.40+0.07
6 hrs 0.52iO.21 0.51+0.09
8 hrs 0.51+0.19 0.47iO.10
10 hrs 0.46+0.21 0.46+0.13
: l 1 24 hrs 0.35+0.05 1 0.26+0.09
AUC (0-24 hrs) (~g hr/me) 10.679.07
_
